Yesterday, the Senate passed important legislation regarding additional measures to ensure the safety and quality of compounded pharmaceutical products, better known as the Drug Quality and Security Act.
“The Senate is to be commended for passing the Drug Quality and Security Act,” said FAH President and CEO Chip Kahn. “This much-needed legislation will help ensure that consumers have peace of mind about the safety and quality of compounded prescription drugs. It also is important that the measure assures the ability of hospitals to provide patients with the safe, reliable and effective pharmaceutical products required for their care.”
As outlined in an earlier blog post this summer, compounded pharmaceuticals are essential in meeting physician and patient preferences for particular prescriptions and for addressing occasional drug shortages or unavailability of critical medications. For example, if a patient has a particular allergy to an ingredient in a mainstream drug, compounding can create a version of that medication that is safe for the patient to use to treat their condition.
Although compounding is important to ensuring every patient has access to the best medication suited for their needs, the necessity for supervision and accountability is clear. Responsible oversight of pharmaceutical compounding facilities is extremely important to hospitals, as protecting our patients is always priority number one.
HR 3204, the Drug Quality and Security Act, puts in place additional safeguards to protect pharmacies and patients to ensure drug compounding occurs in a safe manner. The bill requires compounded drug manufacturers to disclose outsourcing facilities by requiring annual registration, which subjects these facilities to the jurisdiction of federal manufacturing regulations and would also incentivize supervision by cutting red tape if proper safety procedures are supervised by a licensed pharmacist in the outsourcing facility. This bill is especially important because there is currently no mechanism for tracking prescription drugs in the U.S., and consumers can be exposed to stolen, ineffective or counterfeit pharmaceuticals.
“It is noteworthy that this important legislation had strong, bipartisan support in the Senate and in the House, which passed the bill earlier this year,” Kahn added. “We look forward to it being signed quickly into law.”